Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- Conditions
- Thyroid CancerPapillary Thyroid CancerFollicular Thyroid CancerThyroid Cancer, MedullaryDifferentiated Thyroid CancerPoorly Differentiated Thyroid Gland Carcinoma
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-07-14
- Target Recruit Count
- 6
- Registration Number
- NCT03630120
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
- Conditions
- NSCLC, Stage IIIANSCLCNon Small Cell Lung CancerNSCLC Stage IIIBNon-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage ⅢANon-small Cell Lung Cancer
- Interventions
- Dietary Supplement: Impact® Advanced RecoveryDietary Supplement: Boost® High ProteinRadiation: Radiation TherapyDrug: ChemotherapyOther: Quality of life (EORTC-QLQ-30)Other: Evaluation of Cognitive Function (FACT-Cog, v. 3.0)Other: Mindfulness Questionnaire (FFMQ)
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
- Conditions
- Cervical Cancer RecurrentCervical Cancer MetastaticCervical Cancer
- Interventions
- Radiation: Stereotactic body radiation therapy (SBRT)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 21
- Registration Number
- NCT03614949
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Ohio State University - OSUMC - Wexner Medical Center, Hilliard, Ohio, United States
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
- Conditions
- Non-small Cell Lung CancerLung CancerEGFR Negative Non-Small Cell Lung CancerNon-small Cell Lung Cancer MetastaticStage IV Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIB
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 21
- Registration Number
- NCT03611738
- Locations
- 🇺🇸
Advent Health Orlando, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
- Conditions
- Chronic Myeloid Leukemia, Chronic PhaseChronic Phase Chronic Myeloid Leukemia
- Interventions
- Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2025-05-11
- Target Recruit Count
- 24
- Registration Number
- NCT03610971
- Locations
- 🇺🇸
Emory -Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering - Bergen, Montvale, New Jersey, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
- Conditions
- GVHD, AcuteGraft-versus-host-diseaseGVHD
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2025-02-12
- Target Recruit Count
- 45
- Registration Number
- NCT03605927
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
- Conditions
- Lung DiseasesLung Cancer, Protection Against
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 19
- Registration Number
- NCT03598309
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
- Conditions
- Refractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic LeukemiaLymphoid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 11
- Registration Number
- NCT03575325
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
- Conditions
- Skin CarcinomaMelanoma (Skin)Skin MelanomaSkin Cancer
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 14
- Registration Number
- NCT03543969
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
- Conditions
- Prostate DiseaseProstate Cancer
- Interventions
- Radiation: BrachytherapyRadiation: External Beam Radiation TherapyDrug: Androgen Deprivation Therapy
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 44
- Registration Number
- NCT03543189
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States